Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...

Placebos appear to reduce PMS symptoms

Women affected by premenstrual syndrome (PMS) appear to experience less intense and debilitating...

Medicinal cannabis linked to long-term health benefits

As scientists find a way to improve the effectiveness of CBD, a separate study shows that...

Content from other channels on our network

New membranes could help eliminate brine waste at desalination plants

Emissions as data: the challenge of reporting on an invisible metric

Fluoride boosts water-processed perovskite solar cells

New filter tech targets PFAS in water

Reaching net zero in the manufacturing sector

Yokogawa to supply integrated SCADA for Melbourne Water

A process of evolution: creating an adaptive future for the industrial workforce

Australian industry contracts in F‍-‍35 program worth over $5 billion

Newmont deploys 'world‍ first' 5G teleremote dozer fleet at Cadia mine

Mitsubishi and Rio Tinto to participate in hydrogen‍-‍based ironmaking

Audit: Northern Beaches Hospital partnership "at risk of failure"

Healthscope issues statement on three hospital patient deaths

Six big ideas for beating brain cancer

National Allied Health Workforce Strategy: a lasting reprieve?

RACP: nationwide issues underpin last week's doctors' strike